Josh Duhamel Defies Hollywood Warnings to Promote Testosterone Therapy
Actor Josh Duhamel, 53, has publicly endorsed testosterone replacement therapy (TRT) after discovering low levels in his early 40s. He co-founded Gatlan, a men's health company, despite warnings from former representatives that the venture could damage his image. Duhamel reports feeling stronger and more energetic, injecting testosterone three times weekly. Experts caution that TRT is for medical deficiency, not performance enhancement, and carries risks including infertility and blood clots.
Key points
- Duhamel began TRT after testing low in his early 40s and now injects three times a week.
- He co-founded Gatlan, a physician-guided men's health company, to promote safe hormone optimization.
- Former representatives warned him that public association with TRT could harm his career and invite ridicule in Hollywood.
- Duhamel reports improved joint health, back strength, and energy levels, stating he feels better than in his 30s.
- Medical experts emphasize TRT is for confirmed deficiency, not enhancement, and warn of risks like infertility and blood clots.
Background
Duhamel's TRT journey began around 2021 after discovering low levels. He previously discussed the therapy on the 'Human Upgrade' podcast, noting it helps him manage his busy life as a father of three. His family is based in Fargo, ND, and a remote retreat in Minnesota, while he maintains a home in Los Angeles for his son Axl's schooling. This follows earlier coverage of his family dynamics and real estate moves.
How outlets are covering it
USA Today focuses on the medical aspects of TRT, highlighting expert opinions on risks and proper diagnosis. Realtor.com emphasizes the personal and professional fallout, detailing Duhamel's fears of being mocked in Hollywood and his decision to prioritize his health over industry pressure. Both sources agree on his current regimen and the founding of Gatlan, but USA Today provides more clinical context while Realtor.com offers insight into his lifestyle and real estate decisions.
Why it matters
Duhamel's public stance highlights the growing popularity of TRT among men, particularly in entertainment. His experience underscores the tension between personal health choices and public image, while also drawing attention to the need for medical oversight in hormone therapy. The story reflects broader trends in men's health and the increasing normalization of TRT, despite potential risks.
What to watch
Duhamel will continue to promote Gatlan and advocate for responsible TRT use. The company may expand its services, and his public visibility could influence public perception of hormone therapy. Medical experts will likely continue to emphasize the importance of proper diagnosis and monitoring for those considering TRT.
Want the full story? Read the original reporting
Read on USA Today